The Digital Biomarker Revolution: How Large-Scale, Clinical-Grade AI Enables Novel CDXs from Histopathology

Presenter: Thomas Fuchs, | Founder and Chief Scientific Officer, Paige

At NASA, we were confronted daily with Goldin’s modified adage: "faster, better, cheaper; pick two". In healthcare, it is becoming drastically more important with the development and validation of increasingly more complex biomarkers for prognostic and predictive purposes. This idea becomes even more relevant as multiple testing methodologies are required to generate all the information needed to make treatment decisions. Many hospital pathology labs are not equipped to perform all the recommended testing, necessitating the tests to be sent out, limiting patient access, and utilizing expensive testing with no promise of an actionable result.

Digital Biomarkers are drastically changing the companion diagnostic (CDX) landscape. These novel data-driven approaches build on Paige’s experience with large-scale clinical systems that are constantly validated on tens of thousands of patients. 

During this webinar, the presenter will:

  1. Discuss why now: What changed in Pathology and AI that allowed this breakthrough at this moment in time
  2. Explain hype vs. reality: What AI can deliver and what it cannot. Who to differentiate real evidence from hot air?
  3. Explore what will the future of digital biomarkers look like in the near-term and the long-term

Register for On-Demand Access:



Founder and Chief Scientific Officer, Paige

Dr. Fuchs is the Founder and Chief Scientific Officer (CSO) at Paige. Dr. Fuchs is a pioneer in computational pathology and also an Associate Professor of Machine Learning at Weill-Cornell Graduate School of Medical Sciences. He also serves as the Director of The Warren Alpert Center for Digital and Computational Pathology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. Previously, Dr. Fuchs served as a research technologist at NASA’s Jet Propulsion Laboratory in Pasadena, focusing on space exploration research. He earned his Dr.Sc. from ETH and received his M.Sc. (Dipl.-Ing.) from Technical University Graz. He was named one of the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare in 2019.

Dr. Fuchs and his colleagues from MSKCC founded Paige in 2017. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. Paige is the first company to receive FDA clearance and FDA breakthrough designation for computational pathology products.